Equity Analysis /

US : Aerie Pharmaceuticals, Inc. - AERI | Weekly Rx Metrics

Elliot Wilbur

CFA @ CGS-CIMB

Lucas Lee

Sr. Res. Assoc. @ CGS-CIMB

25 January 2021

Published byCGS-CIMB

Share this report

Updated product metrics based on weekly prescription trends for key Aerie Pharmaceuticals products are herein. With the latest weekly Rxs, we estimate Aerie’s combined glaucoma franchise is annualizing at $81M in sales.RhopressaRhopressa is in its 32nd month of full-scale launch, and the latest wee

Share this report

Most ViewedSee latest

Disclosures:

This publication is being distributed by Tellimer solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not constitute investment recommendation, and nor is it investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument.

This publication is not intended for distribution to, or use by, any person or entity in any jurisdiction in any country where such distribution or use would be contrary to law or regulation, or which would subject Tellimer to any registration requirement within such jurisdiction or country.

Full Tellimer disclaimers